Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers
出版年份 2022 全文链接
标题
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers
作者
关键词
APRIL, clinical trial, galactose-deficient IgA, glomerulonephritis, IgA nephropathy, monoclonal antibody
出版物
Kidney International Reports
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-02-08
DOI
10.1016/j.ekir.2022.01.1073
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
- (2021) Vivien Hébert et al. Frontiers in Immunology
- Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
- (2020) Celine Kaegi et al. Frontiers in Immunology
- A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy
- (2019) James R. Myette et al. KIDNEY INTERNATIONAL
- A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy
- (2019) Miki Takahara et al. CELLULAR IMMUNOLOGY
- TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA nephropathy
- (2019) Yuko Makita et al. KIDNEY INTERNATIONAL
- Concept of Pharmacologic Target‐Mediated Drug Disposition in Large‐Molecule and Small‐Molecule Compounds
- (2019) Guohua An JOURNAL OF CLINICAL PHARMACOLOGY
- Regulation of IgM+ B Cell Activities by Rainbow Trout APRIL Reveals Specific Effects of This Cytokine in Lower Vertebrates
- (2018) Irene Soleto et al. Frontiers in Immunology
- Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han population
- (2017) Zhong Zhong et al. JOURNAL OF GENE MEDICINE
- Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy
- (2016) Masahiro Muto et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
- (2016) Richard A. Lafayette et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy
- (2016) S. S. Han et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy
- (2016) Ya-Ling Zhai et al. MEDICINE
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
- (2014) David Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens
- (2014) Krzysztof Kiryluk et al. NATURE GENETICS
- Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial
- (2012) Rodney P E Pollard et al. ANNALS OF THE RHEUMATIC DISEASES
- Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
- (2012) Ellen M Ginzler et al. ARTHRITIS RESEARCH & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now